Lonza plans to construct a large-scale commercial drug product fill and finish facility in Stein, Switzerland. The investment will enable the company to provide customers with a complete and integrated end-to-end solution that includes commercial drug product manufacturing for large-scale market supply, according to Pierre-Alain Ruffieux, CEO, Lonza. The new facility will be delivered through an investment of approximately $520 million and is expected to be completed in 2026, he explained.
“Combined with our strong drug substance manufacturing footprint, the new facility will enable us to provide customers with an integrated end-to-end offering across their entire product life cycle,” said Ruffieux.
“Building on our experience and expertise in addressing drug product development, formulation and manufacturing challenges, this new facility will enable us to capture additional market share and fulfill sustained customer demand for commercial drug product manufacturing,” added Jean-Christophe Hyvert, president, biologics and cell & gene, Lonza.
Since establishing drug product development and manufacturing services in 2016, Lonza has expanded its clinical drug product offering in Basel, Visp, and Stein, and Guangzhou in China. The new facility will be constructed in Stein on the same campus as Lonza’s current clinical drug product facility, allowing the company to leverage the existing infrastructure, capabilities, and talent, noted Hyvert, who pointed out that the facility will embrace the latest developments in sustainable construction, taking a modern approach to carbon reduction and responsible energy use, including the installation of a photovoltaic roof.
For more on Lonza’s recent activities, see Lonza and the Israel Biotech Fund Ink Development and Manufacturing Deal and Lonza and Integral Molecular Offer to Enhance Early De-Risking of Clients’ Biotherapeutics.
